Macleod A M, Hillis A N, Mather A, Bone J M, Catto G R
Lancet. 1987 Feb 21;1(8530):416-8. doi: 10.1016/s0140-6736(87)90121-8.
Non-cytotoxic and cytotoxic antibodies were sought after donor-specific transfusion (DST) in 12 potential renal transplant recipients given concomitant cyclosporin therapy and 13 given DST alone. Non-cytotoxic antibodies, which have been shown to develop after third-party transfusion and to be associated with successful transplantation, developed after DST whether or not cyclosporin was given. Donor and panel reactive lymphocytotoxic antibodies developed relatively infrequently after DST with or without cyclosporin. Donor-specific sensitisation occurred only in patients who were multiparous or had over 10 third-party transfusions. Non-cytotoxic Fc-receptor-blocking antibodies may play a part in the improved survival of one-haplotype-mismatched transplants pretreated with DST.
在12例接受环孢素联合治疗的潜在肾移植受者和13例仅接受供者特异性输血(DST)的患者中,研究了非细胞毒性抗体和细胞毒性抗体。已证明非细胞毒性抗体在接受第三方输血后会产生,并与移植成功相关,无论是否给予环孢素,DST后都会产生这种抗体。无论有无环孢素,DST后供者和群体反应性淋巴细胞毒性抗体的产生相对较少。供者特异性致敏仅发生在多产或接受过10次以上第三方输血的患者中。非细胞毒性Fc受体阻断抗体可能在经DST预处理的单倍型错配移植的存活率提高中发挥作用。